Peter Thiel-backed AbCellera Biologics Inc said on Wednesday it had entered a multi-year agreement with Covid-19 vaccine maker Moderna Inc to develop antibody therapies for multiple diseases, according to Reuters.
The biotech company said Moderna would have rights to develop and sell the antibodies, based on its mRNA technology, resulting from the collaboration.
AbCellera will receive research payments and is eligible to receive milestone payments as well as royalties on the sales of the antibodies, it said.
